
Taisho Pharmaceutical is a Japanese pharmaceutical company with a rich history dating back to 1899. It was founded by Yoshitoshi Yoda and has since grown into a major player in the industry.
The company's business information reveals that it has a diverse portfolio of products, including prescription drugs, over-the-counter medications, and health foods. This diversification has enabled Taisho to maintain a strong presence in the market.
Taisho's structure is also noteworthy, with a global network of subsidiaries and affiliates operating in over 30 countries worldwide. This international presence has allowed the company to expand its reach and cater to diverse customer needs.
Taisho's commitment to innovation is evident in its research and development efforts, which focus on developing new products and improving existing ones.
Related reading: Johnson & Johnson - Merck Consumer Pharmaceuticals Company
Ownership and Structure
Taisho Pharmaceutical's stock is traded on the Tokyo Stock Exchange.
The principal owners of the firm are the Uehara family name, who hold significant control over the company.
Ownership

Taisho Pharmaceutical's stock is traded on the Tokyo Stock Exchange. The company's ownership structure is centered around the Uehara family name, who are the principal owners of the firm.
SIC Code for Ltd
I've worked with companies that have a limited liability structure, and one important piece of information is the SIC code. The SIC code for TAISHO PHARMACEUTICAL CO., LTD. is 67, 671.
Having a clear SIC code can help with business registration and compliance. The SIC code for TAISHO PHARMACEUTICAL CO., LTD. is specifically 67, 671, which indicates the type of business it is.
Understanding the SIC code can also help with industry classification. In the case of TAISHO PHARMACEUTICAL CO., LTD., the SIC code is 67, 671, which falls under the category of "Chemicals and Allied Products".
On a similar theme: Bank Transfer Swift Code
Leadership and Management
At the helm of Taisho Pharmaceutical is Satoshi Ozaki, who serves as the company's President. He brings a wealth of experience and leadership to the role.
Taisho Pharmaceutical is fortunate to have a seasoned leader like Satoshi Ozaki guiding the company's direction.
Financial Information
Taisho Pharmaceutical is a major player in the industry, and its financials are a great place to start. The company's annual revenue was $3 billion in 2025.
Taisho Pharmaceutical has a significant presence in the market, and its financials reflect that.
The company's annual revenue of $3 billion in 2025 is a testament to its success.
Location and Operations
Taisho Pharmaceutical is a Japanese company with a strong presence in the pharmaceutical industry. It is based in Tokyo, Tokyo.
The company has a significant presence in this location, which is likely due to its proximity to major research institutions and hospitals.
Taisho Pharmaceutical's headquarters is located in Tokyo, Tokyo, which is a hub for business and innovation in Japan.
The company's location in Tokyo allows it to easily collaborate with other businesses and organizations in the area.
Taisho Pharmaceutical's operations are likely streamlined due to its centralized location in Tokyo, Tokyo.
Products and Services
Taisho Pharmaceutical has been busy with new product plans. In 2024, the company announced its plans to introduce a new throat lozenge called Vicks Medicated Drops Honey, which contains the antiseptic ingredient CPC.
The company also plans to launch CBD Taisho, a supplement containing the plant-derived ingredient CBD, in 2024. This is a significant move into the CBD market.
Taisho Pharmaceutical is expanding its product portfolio with new quasi-drug mini-drinks called Lipovitan Walk and Lipovitan Active, scheduled to be launched in April 2024.
Products and Services
Taisho Pharmaceutical Holdings Co Ltd has been making waves in the market with its new product launches. The company has announced plans to introduce a new throat lozenge containing the antiseptic ingredient CPC (cetylpyridinium chloride hydrate), Vicks Medicated Drops Honey, in September 2024.
In addition to the throat lozenge, Taisho Pharmaceutical Holdings Co Ltd is also set to launch CBD Taisho, a supplement containing the plant-derived ingredient CBD (cannabidiol), in September 2024.
The company has a history of innovative product launches, and its plans to introduce new products are certainly worth keeping an eye on. Lipovitan Walk and Lipovitan Active, quasi-drug mini-drinks, are also set to be launched in April 2024.
Here's a summary of the new products and services announced by Taisho Pharmaceutical Holdings Co Ltd:
Competitor Comparison
When looking at the Japanese pharmaceutical industry, it's worth noting that all five major players have their headquarters in Japan.
Taisho Pharmaceutical Holdings Co Ltd has a significant presence with 8,784 employees, but Otsuka Holdings Co Ltd has a much larger workforce with 35,338 employees.
Astellas Pharma Inc and Daiichi Sankyo Co Ltd are both public companies, which is a common entity type among the major players in the industry.
Here is a comparison of the key parameters of the five major Japanese pharmaceutical companies:
The city of Tokyo seems to be the hub for these pharmaceutical companies, with all five having their headquarters located there.
Research and Development
Taisho Pharmaceutical has a robust clinical trials process in place, as seen in their go-to-market proposition. They conduct thorough clinical operations to ensure the success of their trials.
Their recruitment strategy is key to the success of their clinical trials, allowing them to attract the right participants for their studies.
Clinical Trials
In clinical trials, Taisho Pharmaceutical Holdings Co Ltd focuses on determining the effectiveness of their products.
Taisho Pharmaceutical Holdings Co Ltd has a go-to-market proposition that involves clinical operations, recruitment, and trial strategy.
The company's clinical trials are a crucial step in bringing new products to market.
To gain insight into the company's clinical operations, we can look at their recruitment strategy, which involves identifying and enrolling participants for their trials.
Consider reading: Global Strategy Group
Regulatory Milestones
In the world of research and development, regulatory milestones are a crucial aspect to consider. Track drug and patent expiries along with geographies impacted to stay ahead of the game.
As you navigate the complex landscape of pharmaceuticals, it's essential to keep track of expiring patents and drugs. This information can help you make informed decisions about your research and development pipeline.
Regulatory milestones can also inform your marketing and sales strategies. By understanding which geographies are impacted by expiring patents and drugs, you can tailor your approach to meet the needs of specific regions.
In many cases, regulatory milestones can have a significant impact on the pharmaceutical industry. This is evident in the fact that tracking drug and patent expiries along with geographies impacted is a key regulatory milestone.
For more insights, see: Yorkshire Patent Steam Wagon Co.
Frequently Asked Questions
What is the history of Taisho Pharma?
Taisho Pharmaceuticals was founded in early 1912 in Tokyo, Japan, with a mission to improve health standards and community growth. Since its inception, the company has been dedicated to enhancing the well-being of individuals and communities.
Featured Images: pexels.com


